Overview

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Treatments:
Tretinoin